FDA Requests Updated E2100 Data for Avastin sBLA Review

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 10
Volume 15
Issue 10

Before it will consider Genentech's supplemental Biologics License Application (sBLA) for Avastin (bevacizumab) plus chemotherapy as first-line treatment of metastatic breast cancer

SOUTH SAN FRANCISCO, California—Before it will consider Genentech's supplemental Biologics License Application (sBLA) for Avastin (bevacizumab) plus chemotherapy as first-line treatment of metastatic breast cancer, FDA wants to see a substantial safety and efficacy update from the pivotal E2100 trial. E2100 randomized metastatic breast cancer patients to receive paclitaxel with or without Avastin every 2 weeks. The request includes an independent review of patient scans for progression-free survival.

The company said in a press release that it has received a Complete Response Letter from FDA, indicating that a new 6-month review period will begin once the additional information requested is submitted.

Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer